RECRUITING

Testing Use of Topical Imipramine in Reducing Ultraviolet B Induced Microvesicle Particle Release in Photosensitive Subjects

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is three-fold. First, researchers will assess whether subjects who have clinically abnormal reactions to sunlight (photosensitivity) have increased levels of microvesicle particles (MVP) following ultraviolet B (UVB) treatment to localized area of skin. Second, researchers will assess if topical application of the medicine imipramine will block UVB-induced MVP release. Third, researchers will assess if the topical cream will block UVB-induced increased erythema reactions (reddening of the skin).

Official Title

Pilot Studies Testing Use of Topical Imipramine in Reducing Ultraviolet B Induced Microvesicle Particle Release in Photosensitive Subjects

Quick Facts

Study Start:2022-06-06
Study Completion:2026-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04520217

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 50 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * Female and Male adult subjects age 18 to 50
  2. * Must be able to give informed consent
  3. * Have access to stable transportation
  4. * All skin types on Fitzpatrick Scale (Type I-VI)
  5. * Self-Identified photosensitivity
  6. * Able to provide medical history and list of medications-control subjects will not be allowed to be taking a medication that is known to be photosensitizer.
  1. * Underlying diseases that could affect wound healing (e.g., uncontrolled diabetes mellitus)
  2. * Taking medications that are known photosensitizers (e.g., doxycycline) or anti-inflammatories (e.g., NSAIDS \[except for low-dose aspirin\] or steroids)
  3. * Utilizing imipramine or any other tricyclic antidepressant (oral or cream)
  4. * Utilizing topical anti-inflammatory or systemic agents (e.g., prednisone)
  5. * Large tattoos in the designated testing areas
  6. * Tanning bed use within last 3 months
  7. * Photodynamic Therapy or UVB treatments in past 3 months
  8. * Female Subjects: pregnant or nursing
  9. * History of abnormal scarring (i.e., keloids)

Contacts and Locations

Study Contact

Manager Clinical Research Operations
CONTACT
937-245-7500
pturesearch@wrightstatephysicians.org
Regulatory Specialist
CONTACT
937-245-7500
pturesearch@wrightstatephysicians.org

Principal Investigator

Jeffrey B Travers, MD, PhD
PRINCIPAL_INVESTIGATOR
Wright State University

Study Locations (Sites)

Wright State Physicians
Fairborn, Ohio, 45324
United States

Collaborators and Investigators

Sponsor: Wright State University

  • Jeffrey B Travers, MD, PhD, PRINCIPAL_INVESTIGATOR, Wright State University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-06-06
Study Completion Date2026-12

Study Record Updates

Study Start Date2022-06-06
Study Completion Date2026-12

Terms related to this study

Additional Relevant MeSH Terms

  • Photosensitivity
  • Microvesicle Particle